Posters and Presentations

CGRP Platform

Rimegepant

Date Title Document
A Phase 1 Study to Evaluate the Bioequivalence of Oral Tablet and Orally Dissolving Tablet Formulations of Rimegepant, a Small Molecule CGRP Receptor Antagonist PDF
Rimegepant 75 mg, an Oral Calcitonin Gene-Related Peptide Antagonist, for the Acute Treatment of Migraine: Two Phase 3, Double-Blind, Randomized, Placebo-Controlled Trials PDF
Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-Blind, Randomized, Placebo-Controlled Trial, Study 302 PDF
Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-Blind, Randomized, Placebo-Controlled Trial, Study 301 PDF
Rimegepant and BHV-3500, Small Molecule CGRP Receptor Antagonists, Exhibit No Active Vasoconstrictive Properties in Ex Vivo Human Coronary or Cerebral Arteries PDF
A Phase 1 Study to Evaluate the Bioequivalence of Oral Tablet and Orally Dissolving Tablet Formulations of Rimegepant in Healthy Adult Subjects Under Fasting Conditions PDF
Rimegepant Phase 3 Update and Clinical Perspectives PDF

BHV-3500

Date Title Document
Rimegepant and BHV-3500, Small Molecule CGRP Receptor Antagonists, Exhibit No Active Vasoconstrictive Properties in Ex Vivo Human Coronary or Cerebral Arteries PDF

Glutamate Platform

BHV-0223

Date Title Document
Open-Label, Single-Dose Study of BHV-0223 Zydis® Sublingual Formulation in Participants with ALS Who Have Dysphagia PDF
A Phase 1 Study to Evaluate Bioequivalence Between BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet in Healthy Volunteers PDF
Assessing Effects of BHV-0223 40 mg Zydis® Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym® PDF
Adherence to Riluzole Therapy Improves Clinical Outcomes in ALS Patients: A Claims-Based Longitudinal Comparative Effectiveness Analysis PDF

Troriluzole

Date Title Document
Efficacy and Safety of Troriluzole (BHV-4157) in Patients with Mild to Moderate Alzheimer’s Dementia: T2 PROTECT AD Phase 2/3 Study Design PDF

MPO Platform

No presentations available